Arvinas, Inc. (NASDAQ:ARVN) Shares Acquired by Kennedy Capital Management LLC

Kennedy Capital Management LLC lifted its holdings in Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 42.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 208,992 shares of the company's stock after purchasing an additional 61,802 shares during the period. Kennedy Capital Management LLC owned about 0.30% of Arvinas worth $4,006,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Invesco Ltd. boosted its stake in Arvinas by 1.6% in the fourth quarter. Invesco Ltd. now owns 37,254 shares of the company's stock valued at $714,000 after acquiring an additional 581 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Arvinas by 0.9% in the 4th quarter. Rhumbline Advisers now owns 87,877 shares of the company's stock worth $1,685,000 after purchasing an additional 754 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in Arvinas by 0.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 140,518 shares of the company's stock worth $2,694,000 after buying an additional 777 shares during the last quarter. Bank of Montreal Can increased its position in Arvinas by 2.7% during the 4th quarter. Bank of Montreal Can now owns 39,407 shares of the company's stock valued at $755,000 after buying an additional 1,044 shares in the last quarter. Finally, KBC Group NV boosted its holdings in Arvinas by 77.0% in the fourth quarter. KBC Group NV now owns 2,885 shares of the company's stock worth $55,000 after acquiring an additional 1,255 shares in the last quarter. 95.19% of the stock is currently owned by institutional investors.

Arvinas Price Performance

Shares of ARVN stock traded up $0.95 during trading hours on Friday, hitting $8.60. The company had a trading volume of 3,186,900 shares, compared to its average volume of 1,118,846. Arvinas, Inc. has a fifty-two week low of $5.94 and a fifty-two week high of $37.38. The company's fifty day moving average is $11.67 and its 200 day moving average is $18.76. The stock has a market capitalization of $591.44 million, a PE ratio of -3.10 and a beta of 2.30.

Arvinas (NASDAQ:ARVN - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same quarter last year, the company earned ($2.53) earnings per share. Equities analysts forecast that Arvinas, Inc. will post -3.81 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Wells Fargo & Company set a $26.00 price objective on shares of Arvinas and gave the stock an "overweight" rating in a research note on Wednesday, March 12th. The Goldman Sachs Group decreased their target price on Arvinas from $15.00 to $12.00 and set a "neutral" rating for the company in a report on Thursday. HC Wainwright reissued a "buy" rating and set a $81.00 price target on shares of Arvinas in a research report on Monday, April 7th. Guggenheim dropped their price objective on shares of Arvinas from $57.00 to $32.00 and set a "buy" rating on the stock in a report on Thursday, March 13th. Finally, Wedbush lowered shares of Arvinas from an "outperform" rating to a "neutral" rating and lowered their price target for the company from $57.00 to $12.00 in a report on Wednesday, March 12th. Five equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $34.33.

Insiders Place Their Bets

In other Arvinas news, insider Ian Taylor sold 9,020 shares of the company's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $16.71, for a total transaction of $150,724.20. Following the sale, the insider now owns 159,121 shares in the company, valued at $2,658,911.91. This represents a 5.36 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Noah Berkowitz sold 8,658 shares of Arvinas stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.59, for a total value of $74,372.22. Following the completion of the transaction, the insider now owns 110,023 shares of the company's stock, valued at $945,097.57. The trade was a 7.30 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,230 shares of company stock worth $769,402 over the last three months. Company insiders own 5.23% of the company's stock.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.